Stock Analysis on Net

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX)

$24.99

Return on Capital (ROC)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Return on Invested Capital (ROIC)

Vertex Pharmaceuticals Inc., ROIC calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Net operating profit after taxes (NOPAT)1
Invested capital2
Performance Ratio
ROIC3
Benchmarks
ROIC, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 NOPAT. See details »

2 Invested capital. See details »

3 2024 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


Net Operating Profit After Taxes (NOPAT)
The net operating profit after taxes experienced fluctuations over the observed five-year period. Starting from 3,023,861 thousand US dollars in 2020, it declined sharply to 2,239,320 thousand in 2021. Following this decline, NOPAT recovered to 2,986,401 thousand in 2022 but decreased again to 2,639,623 thousand in 2023. In 2024, there was a significant negative adjustment, with NOPAT turning negative to -1,271,806 thousand US dollars, indicating a substantial loss in operating profit after taxes during this period.
Invested Capital
Invested capital showed a rising trend from 8,144,266 thousand US dollars in 2020 to a peak of 13,278,000 thousand in 2022. It remained relatively stable into 2023 at 13,244,000 thousand before contracting significantly to 9,046,000 thousand in 2024. This contraction in invested capital in the final year suggests a divestment or reduction in the amount of capital employed in operations.
Return on Invested Capital (ROIC)
The return on invested capital exhibited a decreasing trend across most of the period. It started at a high 37.13% in 2020, then sharply declined to 23.86% in 2021. The decline continued more moderately to 22.66% in 2022 and further to 19.93% in 2023. Notably, in 2024 ROIC dropped into negative territory at -14.06%, reflective of the negative operating profit and indicating that the capital invested did not generate returns but instead resulted in losses.
Summary
The data reveal a progressively challenging financial performance over the five years analyzed. While the invested capital initially grew, suggesting expansion or increased investment, the concurrent decline in NOPAT and ROIC indicates diminishing efficiency and profitability in the use of that capital. The sharp negative turn in both NOPAT and ROIC in 2024 highlights a critical downturn, possibly linked to operational difficulties or extraordinary expenses, leading to losses and a retraction of invested capital. This pattern underscores a need for strategic reassessment to restore profitability and effective capital utilization.

Decomposition of ROIC

Vertex Pharmaceuticals Inc., decomposition of ROIC

Microsoft Excel
ROIC = OPM1 × TO2 × 1 – CTR3
Dec 31, 2024 = × ×
Dec 31, 2023 = × ×
Dec 31, 2022 = × ×
Dec 31, 2021 = × ×
Dec 31, 2020 = × ×

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Operating profit margin (OPM). See calculations »

2 Turnover of capital (TO). See calculations »

3 Effective cash tax rate (CTR). See calculations »


Operating Profit Margin (OPM)
The operating profit margin demonstrated a fluctuating pattern over the observed years. It started at a high level of 50.94% in 2020, decreased significantly to 36.91% in 2021, then recovered to 46.55% in 2022 before falling again to 38.69% in 2023. In 2024, there was a drastic decline to a negative margin of -2.19%, indicating a potential operating loss during this period. This suggests increased operational challenges or cost pressures impacting profitability.
Turnover of Capital (TO)
The turnover of capital ratio showed modest variability with an overall upward trajectory. It began at 0.76 in 2020, rose slightly to 0.81 in 2021, and then declined to 0.68 in 2022. Subsequently, it increased to 0.75 in 2023 and experienced a notable rise to 1.22 in 2024. The increase in 2024 suggests a more efficient use of capital to generate sales, despite the deterioration in profitability metrics.
Effective Cash Tax Rate (CTR)
The effective cash tax rate, expressed as 1 minus CTR, declined consistently from 95.66% in 2020 to 69.13% in 2023, indicating a progressive increase in the actual cash taxes paid relative to pre-tax income during this timeframe. However, in 2024, this metric sharply rebounded to 100%, implying either a reversal in tax strategies or a one-time tax effect that resulted in no tax shield or benefits during that year.
Return on Invested Capital (ROIC)
Return on invested capital showed a downward trend over the observed period. Starting from a strong 37.13% in 2020, it declined to 23.86% in 2021 and slightly further to 22.66% in 2022. The deceleration continued in 2023 with a value of 19.93%, before turning negative at -14.06% in 2024. This points to diminishing efficiency in generating returns from invested capital, culminating in an erosion of value in the latest year.
Overall Analysis
The data reflects a challenging environment for the company in recent years. While capital turnover improved notably in 2024—potentially indicating enhanced operational asset management—this was overshadowed by declining profitability and returns. The increasingly adverse operating profit margin and negative ROIC in 2024 highlight significant financial difficulties. Additionally, the effective tax rate dynamics suggest shifting tax obligations or strategies, which may be influencing cash flow outcomes. Together, these trends signal potential operational and financial strains that merit further investigation.

Operating Profit Margin (OPM)

Vertex Pharmaceuticals Inc., OPM calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Net operating profit after taxes (NOPAT)1
Add: Cash operating taxes2
Net operating profit before taxes (NOPBT)
 
Revenues
Profitability Ratio
OPM3
Benchmarks
OPM, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 NOPAT. See details »

2 Cash operating taxes. See details »

3 2024 Calculation
OPM = 100 × NOPBT ÷ Revenues
= 100 × ÷ =

4 Click competitor name to see calculations.


Net Operating Profit Before Taxes (NOPBT)
The net operating profit before taxes exhibited fluctuation over the five-year period. Starting at 3,160,940 thousand US dollars in 2020, it decreased to 2,795,994 thousand in 2021. It then increased significantly to 4,156,831 thousand in 2022, followed by a decline to 3,818,437 thousand in 2023. In 2024, there was a substantial downturn, with the figure dropping sharply to a negative 241,888 thousand US dollars, indicating operating losses before taxes in that year.
Revenues
Revenue demonstrated a consistent upward trend throughout the observed period. Beginning at 6,205,683 thousand US dollars in 2020, revenues increased steadily each year, reaching 7,574,400 thousand in 2021, 8,930,700 thousand in 2022, 9,869,200 thousand in 2023, and culminating at 11,020,100 thousand in 2024. This reflects continual growth in sales or service income over the five-year span.
Operating Profit Margin (OPM)
The operating profit margin showed variability and a notable decline over the period. In 2020, the margin was strong at 50.94%, then decreased significantly to 36.91% in 2021. It recovered somewhat to 46.55% in 2022 but fell again to 38.69% in 2023. By 2024, the margin had turned negative at -2.19%, corresponding with the negative operating profit reported in the same year. This downward movement suggests rising costs or other operational challenges impacting profitability despite revenue growth.

Turnover of Capital (TO)

Vertex Pharmaceuticals Inc., TO calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Revenues
Invested capital1
Efficiency Ratio
TO2
Benchmarks
TO, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Invested capital. See details »

2 2024 Calculation
TO = Revenues ÷ Invested capital
= ÷ =

3 Click competitor name to see calculations.


Revenue Trends
Revenues have shown a consistent upward trajectory from 2020 to 2024. Starting at approximately 6.21 billion US dollars in 2020, revenues increased steadily each year, reaching about 11.02 billion US dollars in 2024. This represents an overall growth of roughly 77.5% over the five-year period, indicating robust expansion in sales or service income.
Invested Capital Fluctuations
The invested capital initially rose from approximately 8.14 billion US dollars in 2020 to a peak of around 13.18 billion US dollars in 2022. It then remained relatively stable in 2023 before declining significantly to about 9.05 billion US dollars in 2024. This pattern suggests an increase in capital investment or asset base until 2022, followed by divestitures or reductions in investment in the subsequent years, particularly notable in 2024.
Turnover of Capital (TO) Analysis
The turnover of capital ratio exhibits variability over the period. It increased slightly from 0.76 in 2020 to 0.81 in 2021, then declined to 0.68 in 2022. In 2023, the ratio improved to 0.75 and showed a significant increase to 1.22 in 2024. The initial decline corresponds with the peak in invested capital, suggesting less efficient use of capital at that time. The marked increase in 2024 indicates improved utilization efficiency, possibly associated with the substantial reduction in invested capital combined with continued revenue growth.
Overall Insights
The company demonstrates strong revenue growth alongside fluctuations in invested capital and capital turnover efficiency. The peak in invested capital in 2022 did not correspond with proportional revenue increases, reflected by a decrease in turnover ratio. However, in 2024, the company achieved higher capital turnover due to both an increase in revenues and a significant reduction in invested capital, suggesting a strategic optimization of capital resources. This pattern indicates an improvement in asset utilization and potentially enhanced operational efficiency in the most recent year.

Effective Cash Tax Rate (CTR)

Vertex Pharmaceuticals Inc., CTR calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in thousands)
Net operating profit after taxes (NOPAT)1
Add: Cash operating taxes2
Net operating profit before taxes (NOPBT)
Tax Rate
CTR3
Benchmarks
CTR, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 NOPAT. See details »

2 Cash operating taxes. See details »

3 2024 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × ÷ =

4 Click competitor name to see calculations.


Over the analyzed period, the cash operating taxes experienced a significant upward trend from 2020 to 2023, with an increase from approximately 137 million to nearly 1.18 billion US dollars. However, in 2024, there was a noticeable decline in cash operating taxes to approximately 1.03 billion US dollars, indicating a reversal of the prior increasing pattern.

Net operating profit before taxes (NOPBT) exhibited fluctuations across the years. In 2020, NOPBT was about 3.16 billion US dollars, which decreased to approximately 2.80 billion in 2021. Subsequently, there was a marked rise to over 4.15 billion in 2022, followed by a moderate decline in 2023 to roughly 3.82 billion. The most significant change was observed in 2024, with NOPBT turning negative, resulting in a loss of approximately 242 million US dollars, indicating deteriorating operational profitability in the most recent period.

The effective cash tax rate (CTR) showed a clear upward trend from 2020 through 2023. It increased from a low of 4.34% in 2020 to 19.91% in 2021, then further rose to 28.16% in 2022, and reached 30.87% in 2023. Data for 2024 was not available, leaving the latest trend incomplete for that year.

Cash Operating Taxes
Steady and substantial increases from 2020 through 2023 with a notable decrease in 2024.
Net Operating Profit Before Taxes (NOPBT)
Experienced volatility with an initial drop in 2021, a peak in 2022, a moderate decline in 2023, and a significant shift to a negative value in 2024.
Effective Cash Tax Rate (CTR)
Consistently rising from a low in 2020 to a higher rate in 2023, showing increased tax burden relative to taxable profits.

Overall, the financial data indicate increasing tax payments relative to operating profits until 2023, with operating profits themselves showing variability and ending with a loss in 2024. The rising effective cash tax rate over most of the period aligns with the increasing taxes paid, despite fluctuating NOPBT. The loss in 2024 suggests operational challenges that may require further investigation.